Previous 10 | Next 10 |
AcelRx Pharmaceuticals ( NASDAQ: ACRX ) is scheduled to announce Q3 earnings results on Monday, November 14th, after market close. The consensus EPS Estimate is -$1.20 and the consensus Revenue Estimate is $0.63M (-66.1% Y/Y). Over the last 3 months, EPS estimates have...
AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022 PR Newswire HAYWARD, Calif. , Nov. 3, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company,...
AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022 PR Newswire The study of 324 complex plastic surgery procedures demonstrated many benefits of using DSUVIA fo...
AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant PR Newswire Physicians across Europe will now have access to DZUVEO®, a novel sublingual approach to acute pain management in medically supervised settings HAYWA...
AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022 PR Newswire Brigham and Wom...
AcelRx Pharmaceuticals ( NASDAQ: ACRX ) dropped ~15% aftermarket as the firm will effect a 1-for-20 reverse stock split on Tuesday at 5.01 pm ET. The company's stock will begin trading on a split-adjusted basis when the market opens on Oct. 26. The reverse spl...
AcelRx Pharmaceuticals Announces Reverse Stock Split PR Newswire HAYWARD, Calif. , Oct. 25, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of ...
AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences PR Newswire Presentation concludes that future battlefield medicine efforts shou...
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference PR Newswire HAYWARD, Calif. , Sept. 6, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the develo...
AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting PR Newswire Experts from the Uniformed Services University of the Health Sciences conclude that future battlefield medicine ...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...